kba1412
High Grade Malignant Neoplasm
Kling Biotherapeutics B.V.Phase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the High Grade Malignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Kling Biotherapeutics B.V. | Phase 1/2 | B |
Cladribine University of Washington | Phase 2 | B |
Evomela University of Washington | Phase 2 | B |
FILGRASTIM University of Washington | Phase 2 | B |
CYCLOSPORIN A University of Washington | Phase 2 | B |
View all 18 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →